Company & Sponsor Intelligence
Tanabe Pharma Corporation
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries1
Therapeutic footprint
alzheimersmovement_disordersschizophrenia
Indexed studies
NCT00862992Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
schizophrenia · JapanPHASE2
schizophrenia · JapanPHASE2
NCT03176771Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
movement_disorders · JapanPHASE2, PHASE3
movement_disorders · JapanPHASE2, PHASE3
NCT01764243Safety and Efficacy of MT-4666
alzheimers · JapanPHASE2
alzheimers · JapanPHASE2
Intelligence layer updated: 2026-11-03 06:12:30.767591+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →